Response, further therapy and outcome of patients with refractory or relapsed ALK‐positive ALCL to ALK‐inhibitor monotherapy in early clinical trials, compassionate use programmes or retrospective analyses. This evidence concerns the gene ALK and anaplastic large cell lymphoma.